Combined use of CSF NfL and CSF TDP-43 improves diagnostic performance in ALS.
Takashi KasaiYuta KojimaTakuma OhmichiHarutsugu TatebeYukiko TsujiYu-Ichi NotoFukiko Kitani-MoriiMakiko ShinomotoDavid AllsopToshiki MizunoTakahiko TokudaPublished in: Annals of clinical and translational neurology (2019)
CSF and plasma NfL may not only serve as diagnostic biomarkers but also provide a measure of disease progression. CSF TDP-43 is also useful as a diagnostic biomarker of ALS, but has no prognostic value. The combined use of CSF NfL and CSF TDP-43 may be a useful biomarker for the diagnosis of ALS.